Orexo AB (publ) Inactive USPTO patentsUtility application

Utility

Pharmaceutical Composition Comprising Adrenaline

9 Nov 23

Jonas SÄVMARKER, Robert RÖNN

Filed: 24 May 23

Utility

New Pharmaceutical Device for Use In Intranasal Administration

5 Oct 23

Jonas SÄVMARKER, Robert RÖNN

Filed: 24 May 23

Utility

8nerae8ok34fur748 1ejscpsvbjdi97nk525lq2dls8d2jiog8hi

24 Mar 22

Jonas SÄVMARKER, Robert RÖNN, Andreas FISCHER

Filed: 2 Dec 21

Utility

two56bm r3g2qtivr3rd

30 Dec 21

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.

Jonas Sävmarker, Robert Rönn, Andreas Fischer

Filed: 10 Feb 21

Utility

ltt43c209njxcfwu0ghplb87vk8wrycq13dfvbqhdpe5xfi67zef52yry3gz

4 Feb 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

sny9p682ykwhtgyl2mpglno4xjdll5fioyp8bbr7jcilivbbzmt8g

14 Jan 21

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.

Jonas Sävmarker, Robert Rönn, Andreas Fischer

Filed: 27 Jul 20

Utility

fvxyt4cs0kxf378 u2wlk3oclww25srvzr3udsj05z9wiz7se4h0

14 Jan 21

According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier.

Jonas Sävmarker, Robert Rönn, Andreas Fischer

Filed: 27 Jul 20

Utility

053u0stcu5efj7tllz5h9vmr040eqb3m1gwioh0ksmzq

14 Jan 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

m3ltkjkslj199ynda 4ykrt4l

14 Jan 21

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 25 Sep 20

Utility

l7rza6p84wwpx39xx4t85wcpc5wghb87 y9cgu32bh52bme

23 Dec 20

There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials.

Andreas Fischer

Filed: 31 Aug 20